The European Patent Office ruled in Sanofi and Regeneron’s favor, invalidating certain claims of Amgen’s European patent directed to antibodies relevant to Praluent.
- Praluent will continue to be available in European countries where it is approved for use and for sale, Sanofi said
- Sanofi has sole rights for Praluent outside the U.S., and Regeneron has sole rights in the U.S.
May 8, Amgen: Japan Supreme Court Rejects Sanofi Appeal on PCSK9 Patent
Aug. 2019, Amgen Patents on Repatha Cholesterol Drug Are Ruled Invalid
To view the source of this information click
To contact the reporter...